**Brian R. Berridge, DVM, PhD, DACVP**

Brian Berridge is Director and Head of WW Animal Research Strategy in the Office of Animal Welfare, Ethics and Strategy at GlaxoSmithKline. In that position he leads efforts to advance the scientific robustness of animal and non-animal modeling in support of pharmaceutical development. He has held previous positions as a Director of Regulatory & Discovery Pathology at GSK and Principal Research Pathologist at Eli Lilly & Company. Brian is an Oklahoma State University-trained veterinarian with residency and PhD training from Texas A&M University. He is a Diplomate of the American College of Veterinary Pathologists and holds an adjunct Associate Professor position in the Department of Population Health and Pathobiology at North Carolina State University. He additionally teaches cardiovascular toxicology at the University of North Carolina. He is a member of the Board of Trustees for the ILSI Health and Environmental Sciences Institute where he also co-chairs the HESI Cardiac Safety Technical Committee as well as the Integrated CV Strategies and Translational Imaging Working Groups. Brian also chairs an international effort to harmonize cardiovascular nomenclature in regulatory toxicologic pathology and a CV Specialty Interest Group within the Society of Toxicologic Pathologists.

**Ellen W. Evans, DVM, PhD, DACVP**

Dr. Evans is Senior Director at the Immunotoxicology Center of Emphasis at Pfizer, Inc. She has a BA in Modern Languages from the College of William and Mary in Virginia and Doctor of Veterinary Medicine from Virginia-Maryland Regional College of Veterinary Medicine at Virginia Tech. After 5 years of private practice in companion animal medicine and surgery, she obtained a PhD in Immunology as well as residency in clinical pathology from the University of Georgia College of Veterinary Medicine. She obtained board certification in clinical pathology by the American College of Veterinary Pathologists in 1994. Dr. Evans was on the faculty at the University of Wisconsin School of Veterinary Medicine prior to joining Schering-Plough Research Institute. At Schering-Plough, she oversaw the clinical pathology, comparative medicine, and immunotoxicology groups and worked with drug development teams to resolve issues related to immunotoxicology and immunomodulation. She joined Pfizer in June of 2010 and currently oversees its Immunotoxicology Center of Emphasis in Groton, CT. Ellen has been a member of the ITC since around 1997 and currently serves as one of its 3 co-chairs, alongside Hervé Lebrec of Amgen and Marc Pallardy of the University of Paris-Sud.

**George Gray, PhD**

George Gray is Professor in the Department of Environmental and Occupational Health and Director of the Center for Risk Science and Public Health (SPHHS). He received his BS in Biology in 1985 from the University of Michigan, his MS in Toxicology in 1988 from the University of Rochester School of Medicine and Dentistry, and his DPhil in 1989 from the University of Rochester School of Medicine and Dentistry. Prior to joining SPHHS in 2010, Professor Gray served as assistant administrator for the U.S. EPA's Office of Research and Development and as the agency science advisor, promoting scientific excellence in EPA research, advocating for the continuing evolution of the agency's approach to analysis, and encouraging programs that provide academic research to support EPA's mission. His areas of focus included nanotechnology, ecosystem research, the influence of toxicology advances on testing and risk assessment, and sustainability. From 2005 to 2009, Professor Gray was executive director of the Harvard Center for Risk Analysis, and a member of the faculty at the Harvard School of Public Health. In addition to teaching, he applied the tools of risk analysis to public health problems ranging from mad cow disease to pesticides in food to the risks and benefits of fish consumption. "Making good public health decisions means assessing what we know, characterizing what we don't, and moving forward." Dr. Gray's primary research interests center around risk characterization, risk communication, and risk policy. He has published on the scientific bases of human health risk assessment, and the ways in which policy considerations influence the risks addressed by regulatory agencies. During his government service Professor Gray served on several committees of the National Science and Technology Council and co-chaired the National Nanotechnology Environmental Health Initiative. He has been a councilor for the Society for Risk Analysis and task force member for the Society of Toxicology. He has served on scientific advisory committees for the FDA Center for Food Safety and Applied Nutrition, and the National Institute of Environmental Health Sciences.

**Heather Joseph, MA**

Heather Joseph serves the Executive Director of the Scholarly Publishing and Academic Resources Coalition (SPARC), an international coalition of academic and research libraries whose mission is to promote the global, cost-effective sharing of scholarly and scientific research results. As SPARC's Director since 2005, she has focused on supporting emerging publishing models, enabling digital archives, and establishing open access policies on the national and international levels.

Prior to joining SPARC, she spent 15 years as a publishing executive in both commercial and not-for-profit publishing organizations, She served as the founding President of BioOne, a collaborative publishing venture in the biological sciences, designed to support non-for-profit publishers.

She continues to be active in the publishing community, and is currently as a member of the Board of Directors of the Public Library of Science. Ms. Joseph has served on the National Advisory Committee for the U.S National Institutes of Health's PubMed Central article archive, and on the U.S. National Academy of Sciences Study Committee on Digital Data Curation. She is a frequent speaker and writer on scholarly communications in general, and on open access in particular.

**Robert S. Langer, ScD**

Robert S. Langer is the David H. Koch Institute Professor (there are 14 Institute Professors at MIT; being an Institute Professor is the highest honor that can be awarded to a faculty member). Dr. Langer has written over 1,200 articles. He also has more than 815 issued and pending patents worldwide. Dr. Langer's patents have been licensed or sublicensed to over 250 pharmaceutical, chemical, biotechnology and medical device companies. He is the most cited engineer in history.

He served as a member of the United States Food and Drug Administration's SCIENCE Board, the FDA's highest advisory board, from 1995 -- 2002 and as its Chairman from 1999-2002.

Dr. Langer has received over 220 major awards including both the 2006 United States National Medal of Science and the 2011 United States National Medal of Technology and Innovation, the 2002 Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers, the 2008 Millennium Prize, the world's largest technology prize, the 2012 Priestley Medal, the highest award of the American Chemical Society and the 2013 Wolf Prize in Chemistry. He is the also the only engineer to receive the Gairdner Foundation International Award; 80 recipients of this award have subsequently received a Nobel Prize. Among numerous other awards Langer has received are the Dickson Prize for Science (2002), Heinz Award for Technology, Economy and Employment (2003), the Harvey Prize (2003), the John Fritz Award (2003) (given previously to inventors such as Thomas Edison and Orville Wright), the General Motors Kettering Prize for Cancer Research (2004), the Dan David Prize in Materials Science (2005), the Albany Medical Center Prize in Medicine and Biomedical Research (2005), the largest prize in the U.S. for medical research, induction into the National Inventors Hall of Fame (2006), the Max Planck Research Award (2008), the Prince of Asturias Award for Technical and Scientific Research (2008), the Warren Alpert Foundation Prize (2011) and the Terumo International Prize (2012). In 1998, he received the Lemelson-MIT prize, the world's largest prize for invention for being "one of history's most prolific inventors in medicine." In 1989 Dr. Langer was elected to the Institute of Medicine of the National Academy of Sciences, and in 1992 he was elected to both the National Academy of Engineering and to the National Academy of Sciences. He is one of very few people ever elected to all three United States National Academies and the youngest in history (at age 43) to ever receive this distinction.

Forbes Magazine (1999) and Bio World (1990) have named Dr. Langer as one of the 25 most important individuals in biotechnology in the world. Discover Magazine (2002) named him as one of the 20 most important people in this area. Forbes Magazine (2002) selected Dr. Langer as one of the 15 innovators worldwide who will reinvent our future. Time Magazine and CNN (2001) named Dr. Langer as one of the 100 most important people in America and one of the 18 top people in science or medicine in America (America's Best). Parade Magazine (2004) selected Dr. Langer as one of 6 "Heroes whose research may save your life." Dr. Langer has received honorary doctorates from Harvard University, the Mt. Sinai School of Medicine, Yale University, the ETH (Switzerland), the Technion (Israel), the Hebrew University of Jerusalem (Israel), the Universite Catholique de Louvain (Belgium), Rensselaer Polytechnic Institute, Willamette University, the University of Liverpool (England), Bates College, the University of Nottingham (England), Albany Medical College, Pennsylvania State University, Northwestern University, Uppsala University (Sweden), Tel Aviv University (Israel), Boston University, Ben Gurion University (Israel) and the University of California – San Francisco Medal. He received his Bachelor's Degree from Cornell University in 1970 and his Sc.D. from the Massachusetts Institute of Technology in 1974, both in Chemical Engineering.

**Harold Zenick, PhD**

Dr. Harold Zenick is Director, National Health and Environmental Effects Research Laboratory (NHEERL) in the Office of Research and Development in the US Environmental Protection Agency (EPA). Dr. Zenick earned a Ph.D. in Physiological Psychology from the University of Missouri (Columbia). He also completed a Post-Doctoral Fellowship in Toxicology at the University of Cincinnati. Before coming to EPA, Dr. Zenick spent 13 years in academia with the Department of Environmental Health in the University of Cincinnati Medical School, preceded by an appointment at New Mexico Highlands University. Dr. Zenick serves on the Executive Board to the National Toxicology Program and as EPA's liaison to NCER-ATSDR's Board of Scientific Councilors. He co-chair the Agency's Biomonitoring Work Group and co-chairs the EPA-NTP Work Group. He has received numerous awards including being a two-time recipient of the prestigious Presidential Meritorious Executive Rank Award and the ORD Statesmanship and Diversity awards. Dr. Zenick has participated on a number of prominent National and Federal work groups and currently serves as co-chair of the Toxics and Risk Subcommittee under the auspices of the Committee on Environment, Natural Resources and Sustainability/Office of Science, Technology and Policy. Within the Society of Toxicology, he has served as the President of three specialty sections; the most recent being the Occupational and Public Health Specialty Section. He also in a member of the HESI Emerging Issues Committee. His current interests are in integrating human health and ecological risk assessment, strengthening the linkages between environmental and public health agendas and agencies, the promotion of sustainability and sustainable problem solutions as a critical consideration in EPA's decision making, and the application of emerging computational, informational and molecule sciences in improving toxicity testing and risk assessment practices.